Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection

Table 1 Clinicopathological features of all patients

Variable	Overall	Adjuvant chemoradiotherapy group	Adjuvant chemotherapy group
	316	57	259
Age, n (%)
< 40 yr	6 (1.9)	2 (3.5)	4 (1.5)
≥ 40 yr	310 (98.1)	55 (96.5)	255 (98.5)
Sex, n (%)
Male	268 (84.8)	46 (80.7)	222 (85.7)
Female	48 (15.2)	11 (19.3)	37 (14.3)
BMI, n (%)
< 18.5 or > 23.9	169 (53.5)	27 (47.4)	142 (54.8)
18.5-23.9	147 (46.5)	30 (52.6)	117 (45.2)
The degree of differentiation, n (%)
Poorly differentiated	233 (73.7)	45 (78.9)	188 (72.6)
Moderately-highly differentiated	83 (26.3)	12 (21.1)	71 (27.4)
Nerve invasion, n (%)
Yes	269 (85.1)	43 (75.4)	226 (87.3)
No	47 (14.9)	14 (24.6)	33 (12.7)
Vascular invasion, n (%)
Yes	263 (83.2)	40 (70.2)	223 (86.1)
No	53 (16.8)	17 (29.8)	36 (13.9)
Pathologic T stage, n (%)
pT1-3	179 (56.6)	34 (59.6)	145 (56.0)
pT4a-4b	137 (43.4)	23 (40.4)	114 (44.0)
Pathologic N stage, n (%)
pN1-2	73 (23.1)	10 (17.5)	63 (24.3)
PN3	243 (76.9)	47 (82.5)	196 (75.7)
Pathological stage, Siewert type II	148 (46.8)	25 (43.9)	123 (47.5)
IIIB stage	30 (9.5)	6 (10.5)	24 (9.3)
IVA stage	118 (37.3)	19 (33.3)	99 (38.2)
Pathological stage, Siewert type III	168 (53.2)	32 (56.1)	136 (52.5)
IIIA	32 (10.1)	1 (1.8)	31 (12.0)
IIIB	80 (25.3)	22 (38.6)	58 (22.4)
IIIC	56 (17.7)	9 (15.8)	47 (18.1)

BMI: Body mass index.